Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus : a pilot trial

• 資料種別: 博士論文
• ISSN: 1349-6867
• タイトル: Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus : a pilot trial
• 巻次・部編番号: 64 1-2
• 著者・編者: Obata, Fumiaki; Tani, Kenji; Yamaguchi, Harutaka; Tabata, Ryo; Bando, Hiroyasu; Imoto, Issei
• 著者標目: Obata, Fumiaki; Tani, Kenji; Yamaguchi, Harutaka; Tabata, Ryo; Bando, Hiroyasu; Imoto, Issei
• 出版事項: Faculty of Medicine Tokushima University
• 出版年月日等: 2017-02
• 出版年（W3CDTF）: 2017-02
• 並列タイトル等: 2型糖尿病患者に対するエンパグリフロジン10mgの連日投与と隔日投与の有効性と安全性の比較検討:パイロット試験; Comparison of treatment in patients
• タイトル（掲載誌）: The Journal of Medical Investigation
• 授与機関名: 徳島大学
• 授与年月日: 2017-04-27
• 授与年月日（W3CDTF）: 2017-04-27
• 報告番号: 甲第3093号
• 学位: 博士（医学）
• 博論授与番号: 甲第3093号
• 本文の言語コード: eng
• 件名標目: sodium-glucose transporter 2 inhibitors; type 2 diabetes mellitus; every other day; empagliflozin; weight reduction
• 対象利用者: 一般
• 一般注記: The terminal elimination half-life (t1/2) of empagliflozin is 13.1 hours. Accordingly, we hypothesized that the administration of empagliflozin every other day might improve glycemic control in patients with type 2 diabetes mellitus, not being inferior to the therapy every day. We investigated the clinical effects and safety of the addition of empagliflozin every day or every other day to type 2 diabetic patients with a poor control in glycemia. Thirteen Japanese patients diagnosed as type 2 diabetes mellitus recruited to this study. Subjects were divided into two groups ; one was treatment with 10 mg of empagliflozin every day (Group A), the other was 10 mg of empagliflozin every other day (Group B). The comparable study of multiple clinical indexes between the 2 groups was made before and 8, 16, and 24 weeks after the treatment. After the treatment for 24 weeks, the HbA1c level was decreased both in group A (from 7.5%±1.1% to 6.5%±0.8%) and in group B (from 7.6%±0.8% to 7.2%±0.5%). This pilot trial suggested the possibility of 10-mg every other day administration with empagliflozin for Japanese patients with type 2 diabetes mellitus.
• DOI: info:doi/10.2152/jmi.64.50; https://doi.org/info:doi/10.2152/jmi.64.50
• 国立国会図書館永続的識別子: info:ndljp/pid/10371160; https://dl.ndl.go.jp/pid/10371160
• コレクション（個別）: 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• 収集根拠: 博士論文（自動収集）
• 受理日（W3CDTF）: 2017-07-03T04:10:06+09:00
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: 国立国会図書館内限定公開
• デジタル化資料送信: 図書館・個人送信対象外
• 遠隔複写可否（NDL）: 可
• 掲載誌（URI）: http://repo.lib.tokushima-u.ac.jp/111081
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

目次

2019-09-09 再収集